The efficacy of zongertinib was evaluated in Beamion LUNG-1, an open-label, multicenter, multi-cohort trial.
Non-Small Cell Lung Cancer
FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ...
Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ...
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.